COMPLIANCE

Urine Drug Testing (UDT) remains in the forefront of prescription drug monitoring and compliance.

UDT must be done routinely as part of an overall best practice program in order to prescribe chronic opioid therapy. This program may include risk stratification; baseline and periodic UDT; behavioral monitoring; and prescription monitoring programs as the best available tools to monitor chronic opioid compliance.
​A combination of monitoring for aberrant behavior and use of UDT has been recommended as the best available monitoring strategy

UDT combined with adherence monitoring has been shown to reduce the occurrence of aberrant drug- taking behaviors.

​By using UDT in a patient-centered fashion, both patient and physician interests are maintained.  Clinical testing can enhance the doctor-patient relationship when the results are used to improve communication. A patient-centered model of UDT should be used to improve quality of care.